Dr. Emily Riehm Meier
Dr. Meier is a board-certified pediatric hematologist/oncologist who provided clinical care for infants, children and adolescents with sickle cell disease and other non-malignant hematologic diseases for 20 years before Global Blood Therapeutics (GBT) as a Senior Medical Director in March 2022. With the acquisition of GBT by Pfizer, she is now a Medical Director for Sickle Cell Disease in Global Medical Affairs and has been seeing patients on a volunteer basis one day a month at Children’s Hospital of Michigan since September 2023.
Dr. Meier received her medical degree from Indiana University School of Medicine and completed her Pediatric Residency, Chief Residency, and Hematology/Oncology fellowship at Children’s National Medical Center in Washington, D.C. After completing her fellowship, she remained at Children’s National as an attending physician in the Division of Hematology for 6 years prior to joining the team at the Indiana Hemophilia and Thrombosis Center (IHTC) in September 2015. She was a research fellow at the National Institutes of Health for 8 years while in Washington, D.C., and was the Director of the Sickle Cell Program at Children’s National from 2011-2013. As the Director of Sickle Cell Research at IHTC, she led Indiana’s hemoglobinopathy newborn screening follow-up program and established an outreach clinic in Gary, IN, a medically underserved community with the second highest incidence of sickle cell disease in Indiana.
